This two-site IRMA includes specific monoclonal antibodies for measuring skeletal alkaline phosphatase (B-ALP) in human serum. Assay calibration is based on mass units (micrograms per liter) and was established with purified B-ALP from a human osteosarcoma cell line, SAOS-2. Precision studies demonstrated intra-and interassay CV5 of 3-5% and 5-7%, respectively. Relative reactivity studies showed that the assay has a sevenfold preference for detecting B-ALP compared with the liver isoenzyme in serum. The normal reference interval for 478 healthy adults was 5-22 .tg/L. Method comparison studies showed good correlation between this B-ALP assay (y) and commercially available electrophoretic methods (x) (y = 0.3540x + 20.5, R2 = 0.929) in a pagetic population. Temporal profiles for total ALP, this IRMA B-ALP assay, and B-ALP by electrophoresis in three pagetic patients were parallel. We conclude that this assay demonstrates good analytical performance and would be useful for the clinical assessment of metabolic bone disorders. 
these measurements are considered useful, they lack specificity because total ALP exists in various isoenzyme forms, resulting from both genetic factors and posttranslational modifications (2). The most common nonskeletal sources of ALP in serum are liver, intestine, placenta, and certain tumors. These sources can contribute to total serum ALP activity, confounding clinical interpretation without fractionation of the ALP isoenzymes (3). For this reason, measurement of the skeletal isoenzyme of ALP (B-ALP) in serum provides a more specific assessment of the metabolic status of bone in normal and pathological conditions. Historically, methods for fractionating and quantitating B-ALP have included heat inactivation (4), agarose gel electrophoresis (5), and wheat germ lectin precipitation (6). With heat inactivation, slight temperature changes modifSr the inactivation rate; therefore, this method, being complex, insensitive, and difficult to perform, has not been used routinely by clinical laboratories. Electrophoretic methods generally exhibit poor resolution, require sample pretreatment, and are technically cumbersome. Precipitation methods with wheat germ lectin do not require special instrumentation but are both complex and indirect, involving several steps and multiple measurements (6) . Recently, an alternative method for B-ALP measurements has been developed. This method, the Tandem#{174}-R Ostasetm (Hybritech, San Diego, CA), is a two-site IRMA that involves specific monoclonal antibodies to measure B-ALP in serum. Measurement of B-ALP alone or in combination with other new methods for assessing bone resorption such as urinary collagen crosslinks (7) may emerge as important assays to monitor therapy and to assess risks in conditions such as osteoporosis and Paget disease of bone. In several studies, the Tandem-R Ostase assay has demonstrated promise as an aid in diagnosing and monitoring bone disorders associated with increased osteoblastic activity (8-13). Here, we present the strategy of the Ostase assay mass calibration, investigate its analytical performance, establish the normal reference interval for adults, and perform a correlation study with electrophoresis.
Our study provides convincing validation for long-term patient monitoring and supports its prospective role in laboratory medicine. The mass estimate of the purified B-ALP preparation (g/L) was then derived from the molarity (molJL) and the molecular mass data (g/mol).
Assay Performance

Subjects.
Specimens from 100 patients (52 men, 48 women), ages 20-97 years (mean 71), were collected under an Institution Review Board-approved protocol. All patients were diagnosed as having Paget disease of bone by either x-rays or bone scans (or both), in combination with total ALP activity measurement. Twothirds of the patients were not receiving treatment at the time the serum sample was obtained. Samples were from patients in Los Angeles, CA; Chicago, IL; Denver, CO; and Lyon, France.
To establish the normal reference interval, we quantified the B-ALP in samples from 478 ostensibly healthy volunteers (217 men, 261 women), ages 20-79 years. Collection and handling of samples. For all studies, whole blood was collected by venipuncture into tubes containing no anticoagulant.
Blood was allowed to clot; serum was separated by centrifugation at l000g for 10 mm. If the serum sample was to be assayed within 24 h of collection, the specimen was stored at 2-8#{176}C; specimens held for longer times were frozen at -20#{176}C or colder. Frozen serum samples were thawed and thoroughly mixed before measurement.
B-ALP measurement. Tandem-R Ostase, a two-site IRMA with two murine monoclonal antibodiesdirected against different antigenic sites on B-ALP, was used to quantifyB-ALP in all human serum samples. The assay is calibrated with a six-point curve constructed from dimeric B-ALP extracted from SAOS-2 cells as described above. Briefly, the assay is performed as follows: Add to a tube 100 jtL of sample and 100 L of 125 
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Purification of B-ALP. Fig. 1 Assay Characteristics Intra-and interassay precision. The precision studies provide a critical evaluation of the long-term consistency of the Ostase assay. The CVs of the low-, medium-, and high-concentration serum control pools in the intraassay study were 4.5%, 3.5%, and 4.2%, respectively; interassay CVs were 6.7%, 7.4%, and 5.9%, respectively, for concentrations ranging from 11.7 to 52.3 jg/L. 
Linearity.
Dilution of serum
An exception to
this was sample L3, for which the relative index increased as the sample dilution progressed, indicating that endogenous B-ALP was most likely contributing to the Ostase-measured reactivity at the lower dilutions. Therefore, only those dilutions for which the relative index reached a constant value were used in the final calculations of the relative index for this sample. The relative index of each sample is shown in Fig. 2 . The mean B-ALP relative index was 38.8 ± 8.6 g/100 U; the mean liver relative index was 5.6 ± 0.3 .tg/100 U.
Recovei'y. Generally, recovery was 100% ± 5%. However, -2 in 100 apparently normal samples were found to underrecover the amount of B-ALP added to the samples.
Serum sample stability. The B-ALP concentrations of samples stored at -20#{176}C ranged from 96% to 101% of the B-ALP concentrations of aliquots of the same samples stored at -70#{176}C over 131 days (Fig. 3) . In addition, serum samples kept at 2-8#{176}C for 72 h and then subjected to five freeze-thaw cycles showed no apparent loss of B-ALP mass measured in the Ostase assay (data not shown). 
Discussion
Calibration for other B-ALP assays is based on enzymatic activity units, and the transition from enzymatic to mass units for assays in general has not always been well-defined. This is especially apparent in mass assays for creatine kinase-MB isoenzyme, in which mass calibration is based on sometimes ifi-defined reference standards, different from the activity calibrators.
In the present study, B-ALP for assay calibrator lots. In this extended interassay study, CVs were also <8%.
To achieve specificity for the skeletal isoenzyme, the Ostase assay includes an immobilized monoclonal antibody to one antigenic site on B-ALP and a second radiolabeled monoclonal antibody to a separate antigemc site on the same molecule. Consequently, the assay exhibits sevenfold preferential binding of the antibodies to the skeletal isoenzyme.
This represents a relative reactivity rather than a cross-reactivity, because the experiment was designed such that one enzyme was not competing with another. The measurement of only one predominant isoenzyme was ensured by diluting the liver ALPand B-ALP-containing serum samples from an initial 10-fold up to 50-or 80-fold, respectively, in heat-inactivated serum. One should perform these studies with human serum ALP isoenzymes because the isoenzymes from either bone or liver tissue are structurally distinct from the corresponding serum forms of ALP (16) (17) (18) with the Ostase assay is stable. Frozen storage has no effect on antigen stability (Fig. 3) , and storing serum samples at 4#{176}C for 72 h followed by five freeze-thaw cycles showed that immunological integrity was maintained (data not shown In the study of Garnero and Delmas (8), the mean (± SD) B-ALP value determined for 353 apparently healthy adults with the Ostase assay was 11.1 ± 4.4 tgfL, with a significant increase after menopause. Because our study was designed to establish a normal reference interval for healthy adults and not to specifically examine the changes in B-ALP in women after menopause, we are unable to confirm or refute the findings of Garnero and Delmas.
The meaxi concentration in 100 serum samples from patients with Paget disease determined with the Ostase assay was 156 ± 152 .tgfL, which correlated well with the electrophoretic method (see Results). The slope corresponds to 35.4 pg of enzyme per 100 U of enzymatic activity, very similar to the mean value of 38.8 j.g/100 U obtained by determining the total ALP and B-ALP in a series of dilutions of five serum samples containing predominantly B-ALP (Fig. 2) . This value indicates the relation between the commonly used enzymatic measurements of ALP in human serum and the mass value reported here.
Various methods have been developed to measure B-ALP. Selective inactivation methods (4) are simple in principle and have been widely used to determine liver ALP directly and B-ALP indirectly in serum samples (24) (25) (26) . However, these methods demand considerable attention to procedural details and are impractical for large sample numbers. Electrophoretic methods (5) allow only visual estimates of the relative proportions of liver ALP and B-ALP; quantification by densitometric scanning is possible only after treatment with neuraminidase.
These procedures also require technical and interpretive expertise and are relatively insensitive. Precipitation methods with wheat germ lectin have been reported, with CVs <10% (6,27). The precipitation assay requires an algorithm to determine the B-ALP activity and coprecipitates some of the nonskeletal ALP fraction in serum. The specificity of wheat germ lectin for B-ALP is reportedly enhanced by pretreatment with Triton X-100. However, liver ALP in serum shows significant interaction with wheat germ lectin in open column chromatography, suggesting that the glycosylation of both skeletal and liver ALP results in interactive N-acetylglucosainine residues (9). The reason for the quantitative separation of ALP isoenzymes in the presence of Triton X-100 is unclear.
We find that the Ostase assay has good performance characteristics and overcomes the limitations of the other methods currently in use for B-ALP quantification. The technical ease, reproducibility, and specificity of this assay provide distinct advantages. 
28). B-ALP concentrations
determined with the Ostase assay were alsosensitive to changes in bone metabolism after the menopause.
In a cross-sectional study of 51 premenopausal and 47 postmenopausal women, Garnero and Delmas reported that the mean B-ALP was 77% higher in the postmenopausal population (8). Considering the advantages of the Ostase assay over the other methods discussed above, we consider the Ostase assay to be the preferred method of quantitating B-ALP in patients with skeletal disorders. More work with the Ostase assay in bone disorders is anticipated.
In conclusion, we find that the reproducibffity, sevenfold preference for detecting B-ALP vs liver ALP in serum, and a detection limit of 0.4 g/L with the Ostase assay are useful in the clinical laboratory. Availability of such an assay for B-ALP determinations may offer an improved clinical tool for evaluating the dynamics of bone metabolism.
